Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.845
+0.005 (0.27%)
Mar 6, 2026, 10:03 AM EST - Market open
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$189,039
Profits / Employee
-$825,104
Market Cap
447.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| REGENXBIO | 353 |
| Lyell Immunopharma | 300 |
| 4D Molecular Therapeutics | 227 |
| Century Therapeutics | 150 |
| Solid Biosciences | 100 |
| Assembly Biosciences | 73 |
| Altimmune | 59 |
LCTX News
- 12 hours ago - Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 hours ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 8 days ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
- 2 months ago - Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
- 2 months ago - Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire
- 4 months ago - Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire